Summary
Germanys Boehringer Ingelheim GmbH filed with regulators in the US, China and Europe to sell a new treatment for lung fibrosis, marking progress for a disease that kills many patients within five years.
Source: Bloomberg
Exclusive AI-Powered News Insights (For Members only)
Disclaimer:This content is AI-generated from various trusted sources and is intended for informational purposes only. While we strive for accuracy, we encourage you to verify details independently. Use the contact button to share feedback on any inaccuracies—your input helps us improve!
